Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ASPH | Q12797 | 1/20 | 0.40 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.40 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.38 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | PYGL | P06737 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7082885 | 0.84 | KEAP1 (0.44) | KEAP1NFE2L2KDM4EASPHKDM8 | |
| SCHEMBL21856903 | 0.83 | TSHR (0.46) | KDM4EMAP2K1ALDH1A1TSHRTP53 | |
| SCHEMBL14331830 | 0.83 | KEAP1 (0.50) | KEAP1NFE2L2KDM4EASPHKDM8 | |
| SCHEMBL28980199 | 0.82 | DGAT1 (0.43) | MAP2K1ALDH1A1TSHRCASP1POLB | |
| SCHEMBL1045113 | 0.81 | KDM4E (0.44) | KEAP1NFE2L2KDM4EASPHKDM8 | |
| SCHEMBL2854043 | 0.81 | CA1 (0.50) | KDM4EALDH1A1TSHRTP53CASP1 | |
| SCHEMBL223134 | 0.81 | KEAP1 (0.53) | KEAP1NFE2L2KDM4EASPHKDM8 | |
| Hydrochloric Acid SCHEMBL17536154 | 0.79 | KDM4E (0.42) | KEAP1NFE2L2KDM4EASPHKDM8 | |
| SCHEMBL22836884 | 0.78 | CFTR (0.45) | ALDH1A1TSHRSMN1; SMN2POLBAPEX1 | |
| SCHEMBL7069337 | 0.78 | KEAP1 (0.46) | KEAP1NFE2L2KDM4EASPHKDM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115724842-A | Pyrimidone derivatives and their use in medicine | 广东东阳光药业有限公司 | 2023-03-03 | — | — | CN | disclosed |
| US-20220259167-A1 | FUROSEMIDE ANALOGUES AND COMPOSITIONS AND USES THEREOF FOR TREATMENT OF ALZHEIMER'S DISEASE | UNIVERSITY HEALTH NETWORK (CA) | 2022-08-18 | — | — | US | disclosed |
| WO-2020257940-A1 | FUROSEMIDE ANALOGUES AND COMPOSITIONS AND USES THEREOF FOR TREATMENT OF ALZHEIMER'S DISEASE | UNIVERSITY HEALTH NETWORK (CA) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020257940-A1 | FUROSEMIDE ANALOGUES AND COMPOSITIONS AND USES THEREOF FOR TREATMENT OF ALZHEIMER'S DISEASE | UNIVERSITY HEALTH NETWORK (CA) | 2020-12-30 | — | — | WO | disclosed |
| EP-3512837-B1 | PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INT (DE) | 2020-07-22 | — | — | EP | disclosed |
| EP-3512837-A1 | PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2 | Boehringer Ingelheim International GmbH (DE) | 2019-07-24 | — | — | EP | disclosed |
| US-10138222-B2 | Substituted benzamides as RIPK2 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-11-27 | — | — | US | disclosed |
| WO-2018052773-A1 | PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-22 | — | — | WO | disclosed |
| US-20180072703-A1 | PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10138222-B2 | Substituted benzamides as RIPK2 inhibitors | RIPK2, RIPK4, RIPK1 | KEAP1 1748/4885NFE2L2 1491/4885KDM4E 751/4885 |
| US-20180072703-A1 | PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2 | RIPK2, RIPK1, RIPK4 | KEAP1 1045/4885NFE2L2 945/4885KDM4E 1911/4885 |
| US-20220259167-A1 | FUROSEMIDE ANALOGUES AND COMPOSITIONS AND USES THEREOF FOR TREATMENT OF ALZHEIMER'S DISEASE | APP, AQP4, BACE1 | KEAP1 537/4885NFE2L2 1015/4885KDM4E 4298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.